Sanjay Mathew

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. pmc Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Drive NE, 3rd Floor, Atlanta, GA, USA
    Trials 15:240. 2014
  2. pmc Ketamine for treatment-resistant unipolar depression: current evidence
    Sanjay J Mathew
    Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA
    CNS Drugs 26:189-204. 2012
  3. pmc A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial
    Sanjay J Mathew
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Eur Neuropsychopharmacol 21:221-9. 2011
  4. ncbi request reprint Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
    J Clin Psychopharmacol 28:235-9. 2008

Collaborators

Detail Information

Publications4

  1. pmc Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Drive NE, 3rd Floor, Atlanta, GA, USA
    Trials 15:240. 2014
    ..This Phase II trial aims to evaluate the efficacy of a CRH type 1 receptor (CRHR1) antagonist in the treatment of PTSD...
  2. pmc Ketamine for treatment-resistant unipolar depression: current evidence
    Sanjay J Mathew
    Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA
    CNS Drugs 26:189-204. 2012
    ..Given the potential risks of ketamine, safety considerations will ultimately determine whether this old drug is successfully repositioned as a new therapy for TRD...
  3. pmc A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial
    Sanjay J Mathew
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Eur Neuropsychopharmacol 21:221-9. 2011
    ..The selective NK(1)R antagonist GR205171 had fewer adverse effects but was not significantly superior to placebo in the short-term treatment of chronic PTSD. (ClinicalTrials.gov Identifier: NCT 00211861, NCT 00383786)...
  4. ncbi request reprint Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
    J Clin Psychopharmacol 28:235-9. 2008
    ..Collectively, these results support further clinical investigation of higher doses of PRX-00023 in anxiety and depression...